Shire Faces Another Challenge To Patent For Adderall XR
Another generic drug maker has launched a challenge against the patent for Shire Pharmaceuticals Group PLC's Adderall XR, a blockbuster drug for the treatment of attention deficit and hyperactivity disorders....To view the full article, register now.
Already a subscriber? Click here to view full article